|Mr. Jonathan Biller J.D.||CFO & Head of Corp. Affairs||804.18k||N/A||1965|
|Dr. Bruce Car Ph.D.||Consultant||776.12k||N/A||1962|
|Dr. Sarah Gheuens M.D., Ph.D.||Chief Medical Officer and Head of R&D||1.57M||72.32k||1980|
|Ms. Richa Poddar||Chief Commercial Officer||624.08k||N/A||1982|
|Mr. Brian M. Goff M.B.A.||CEO & Director||N/A||N/A||1969|
|Dr. Lewis Clayton Cantley Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1949|
|Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1946|
|Dr. Craig B. Thompson M.D.||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||1953|
|Dr. Shin-San Su Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1956|
|Mr. T. J. Washburn Jr.||Principal Accounting Officer||N/A||N/A||1981|
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 31 July 2022 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 7; Compensation: 8.